{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T04:40:07Z","timestamp":1728794407678},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,12]]},"DOI":"10.7759\/cureus.71333","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T04:05:32Z","timestamp":1728792332000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Novel Antiplatelets and Standard Therapy in Patients With Coronary Artery Disease"],"prefix":"10.7759","author":[{"given":"Ravindra Reddy","family":"Gangavarapu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayed A","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anura","family":"Manandhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadeer","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala A","family":"Abdelhady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adoum","family":"Oumar Abakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sondos T","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study","volume":"76","author":"Roth GA","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al.. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020, 76:2982-3021. 10.1016\/j.jacc.2020.11.010","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin SS","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, et al.. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024, 149:e347-913. 10.1161\/CIR.0000000000001209","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon JF","year":"2014","unstructured":"Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014, 114:1852-66. 10.1161\/CIRCRESAHA.114.302721","journal-title":"Circ Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082992","article-title":"Current advances in the diagnostic imaging of atherosclerosis: insights into the pathophysiology of vulnerable plaque","volume":"21","author":"Mushenkova NV","year":"2020","unstructured":"Mushenkova NV, Summerhill VI, Zhang D, Romanenko EB, Grechko AV, Orekhov AN. Current advances in the diagnostic imaging of atherosclerosis: insights into the pathophysiology of vulnerable plaque. Int J Mol Sci. 2020, 21:10.3390\/ijms21082992","journal-title":"Int J Mol Sci"},{"key":"ref5","article-title":"Acute coronary syndrome (unstable angina and non-ST elevation MI)","volume":"2009","author":"Sarkees ML","year":"2009","unstructured":"Sarkees ML, Bavry AA. Acute coronary syndrome (unstable angina and non-ST elevation MI). BMJ Clin Evid. 2009, 2009:","journal-title":"BMJ Clin Evid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27196","article-title":"Platelets in inflammation and atherogenesis","volume":"115","author":"Gawaz M","year":"2005","unstructured":"Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005, 115:3378-84. 10.1172\/JCI27196","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000651","article-title":"Dual antiplatelet therapy for secondary prevention of coronary artery disease","volume":"4","author":"Degrauwe S","year":"2017","unstructured":"Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017, 4:10.1136\/openhrt-2017-000651","journal-title":"Open Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996, 348.1329-39. 10.1016\/s0140-6736(96)09457-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad863","article-title":"The '10 commandments' for the 2023 ESC Guidelines for the management of acute coronary syndromes","volume":"45","author":"Byrne R","year":"2024","unstructured":"Byrne R, Coughlan JJ, Rossello X, Ibanez B. The '10 commandments' for the 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2024, 45:1193-5. 10.1093\/eurheartj\/ehad863","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14317","article-title":"Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis","volume":"86","author":"Yoon HY","year":"2020","unstructured":"Yoon HY, Lee N, Seong JM, Gwak HS. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. Br J Clin Pharmacol. 2020, 86:1489-98. 10.1111\/bcp.14317","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.33963\/v.kp.97391","article-title":"Therapy with ticagrelor\/prasugrel is associated with enhanced fibrinolysis and suppressed platelet activation as compared to clopidogrel in chronic coronary syndrome","volume":"81","author":"Paszek E","year":"2023","unstructured":"Paszek E, Natorska J, Z\u0105bczyk M, Klajmon A, Undas A. Therapy with ticagrelor\/prasugrel is associated with enhanced fibrinolysis and suppressed platelet activation as compared to clopidogrel in chronic coronary syndrome. Kardiol Pol. 2023, 81:1130-3. 10.33963\/v.kp.97391","journal-title":"Kardiol Pol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott SD","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007, 357:2001-15. 10.1056\/NEJMoa0706482","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361:1045-57. 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2797","article-title":"Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study","volume":"113","author":"Kumar A","year":"2023","unstructured":"Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van't Hof JR, Rajpurohit A, Farley JF. Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study. Clin Pharmacol Ther. 2023, 113:401-11. 10.1002\/cpt.2797","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea BJ","year":"2007","unstructured":"Shea BJ, Grimshaw JM, Wells GA, et al.. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007, 7:10.1186\/1471-2288-7-10","journal-title":"BMC Med Res Methodol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001937","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis","volume":"9","author":"Farmakis IT","year":"2022","unstructured":"Farmakis IT, Zafeiropoulos S, Doundoulakis I, et al.. Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis. Open Heart. 2022, 9:10.1136\/openhrt-2021-001937","journal-title":"Open Heart"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014457","article-title":"Efficacy and safety of high potent P2Y(12) inhibitors prasugrel and ticagrelor in patients with coronary heart disease treated with dual antiplatelet therapy: a sex-specific systematic review and meta-analysis","volume":"9","author":"Schreuder MM","year":"2020","unstructured":"Schreuder MM, Badal R, Boersma E, et al.. Efficacy and safety of high potent P2Y(12) inhibitors prasugrel and ticagrelor in patients with coronary heart disease treated with dual antiplatelet therapy: a sex-specific systematic review and meta-analysis. J Am Heart Assoc. 2020, 9:10.1161\/JAHA.119.014457","journal-title":"J Am Heart Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73871-x","article-title":"Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis","volume":"10","author":"Fei Y","year":"2020","unstructured":"Fei Y, Lam CK, Cheung BM. Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep. 2020, 10:10.1038\/s41598-020-73871-x","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-22-7916","article-title":"P2Y12 inhibitors for non-ST-segment elevation acute coronary syndrome: a systematic review and network meta-analysis","volume":"50","author":"Fujisaki T","year":"2023","unstructured":"Fujisaki T, Kuno T, Briasoulis A, Misumida N, Takagi H, Latib A. P2Y12 inhibitors for non-ST-segment elevation acute coronary syndrome: a systematic review and network meta-analysis. Tex Heart Inst J. 2023, 50:10.14503\/THIJ-22-7916","journal-title":"Tex Heart Inst J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2023.11.024","article-title":"Potent P2Y12 inhibitor selection and de-escalation strategies in acute coronary syndrome patients undergoing percutaneous coronary intervention: systematic review and meta-analysis","volume":"6","author":"Boivin-Proulx LA","year":"2024","unstructured":"Boivin-Proulx LA, Bainey KR, Marquis-Gravel G, Graham MM. Potent P2Y12 inhibitor selection and de-escalation strategies in acute coronary syndrome patients undergoing percutaneous coronary intervention: systematic review and meta-analysis. CJC Open. 2024, 6:677-88. 10.1016\/j.cjco.2023.11.024","journal-title":"CJC Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01403-6","article-title":"Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb\/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis","volume":"20","author":"Wang Z","year":"2020","unstructured":"Wang Z, Zhou DY, Su Y, Si LY, Xu Q. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb\/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. BMC Cardiovasc Disord. 2020, 20:10.1186\/s12872-020-01403-6","journal-title":"BMC Cardiovasc Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15059","article-title":"Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y(12) inhibitors compared with clopidogrel","volume":"49","author":"Guo CG","year":"2019","unstructured":"Guo CG, Chen L, Chan EW, Cheung KS, Isshiki T, Wong IC, Leung WK. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y(12) inhibitors compared with clopidogrel. Aliment Pharmacol Ther. 2019, 49:7-19. 10.1111\/apt.15059","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.07.047","article-title":"Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction","volume":"342","author":"Jacobsen MR","year":"2021","unstructured":"Jacobsen MR, Engstr\u00f8m T, Torp-Pedersen C, et al.. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction. Int J Cardiol. 2021, 342:15-22. 10.1016\/j.ijcard.2021.07.047","journal-title":"Int J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa002","article-title":"Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries","volume":"7","author":"De Luca L","year":"2021","unstructured":"De Luca L, Zeymer U, Claeys MJ, et al.. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2021, 7:94-103. 10.1093\/ehjcvp\/pvaa002","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23653","article-title":"Efficacy and safety comparing prasugrel\/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients - a 10-year cohort study","volume":"44","author":"Lam AS","year":"2021","unstructured":"Lam AS, Yan BP, Lee VW. Efficacy and safety comparing prasugrel\/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients - a 10-year cohort study. Clin Cardiol. 2021, 44:1072-9. 10.1002\/clc.23653","journal-title":"Clin Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.25270\/jic\/20.00455","article-title":"Evaluation of a real-world in-hospital antiplatelet-switching strategy following coronary interventions: the SWITCH Study","volume":"33","author":"Soueid AE","year":"2021","unstructured":"Soueid AE, Kassas I, Rade J, Kakouros N. Evaluation of a real-world in-hospital antiplatelet-switching strategy following coronary interventions: the SWITCH Study. J Invasive Cardiol. 2021, 33:263-8. 10.25270\/jic\/20.00455","journal-title":"J Invasive Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15790","article-title":"Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention","volume":"52","author":"Abraham NS","year":"2020","unstructured":"Abraham NS, Yang EH, Noseworthy PA, et al.. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Aliment Pharmacol Ther. 2020, 52:646-54. 10.1111\/apt.15790","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051526","article-title":"No differences in gastrointestinal bleeding risk among clopidogrel-, ticagrelor-, or prasugrel-based dual antiplatelet therapy","volume":"9","author":"Laredo V","year":"2020","unstructured":"Laredo V, Revilla-Marti P, Sostres C, Garc\u00eda S, Carrera-Lasfuentes P, Lanas \u00c1. No differences in gastrointestinal bleeding risk among clopidogrel-, ticagrelor-, or prasugrel-based dual antiplatelet therapy. J Clin Med. 2020, 9:10.3390\/jcm9051526","journal-title":"J Clin Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14213","article-title":"One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: results from a prospective and multicentre ACHILLES registry","volume":"86","author":"Ruiz-Nodar JM","year":"2020","unstructured":"Ruiz-Nodar JM, Esteve-Pastor MA, Rivera-Caravaca JM, et al.. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: results from a prospective and multicentre ACHILLES registry. Br J Clin Pharmacol. 2020, 86:1052-61. 10.1111\/bcp.14213","journal-title":"Br J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1147352","article-title":"P2Y12 inhibitors in acute coronary syndromes: a real-world, community-based comparison of ischemic and bleeding outcomes","volume":"2023","author":"Sachdeva A","year":"2023","unstructured":"Sachdeva A, Mutyala R, Mantri N, Zhu S, McNulty E, Solomon M. P2Y12 inhibitors in acute coronary syndromes: a real-world, community-based comparison of ischemic and bleeding outcomes. J Interv Cardiol. 2023, 2023:10.1155\/2023\/1147352","journal-title":"J Interv Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2018.1445836","article-title":"Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis","volume":"30","author":"Selhorst G","year":"2019","unstructured":"Selhorst G, Schmidtler F, Ott A, et al.. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis. Platelets. 2019, 30:341-7. 10.1080\/09537104.2018.1445836","journal-title":"Platelets"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-001294","article-title":"Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel","volume":"7","author":"Ng AK","year":"2022","unstructured":"Ng AK, Ng PY, Ip A, Lau KK, Siu CW. Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel. Stroke Vasc Neurol. 2022, 7:310-8. 10.1136\/svn-2021-001294","journal-title":"Stroke Vasc Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012078","article-title":"Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study","volume":"8","author":"Yun JE","year":"2019","unstructured":"Yun JE, Kim YJ, Park JJ, et al.. Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study. J Am Heart Assoc. 2019, 8:10.1161\/JAHA.119.012078","journal-title":"J Am Heart Assoc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13304","article-title":"Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients","volume":"50","author":"Gager GM","year":"2020","unstructured":"Gager GM, Jilma B, Winter MP, et al.. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Eur J Clin Invest. 2020, 50:10.1111\/eci.13304","journal-title":"Eur J Clin Invest"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-22-00654","article-title":"Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes","volume":"18","author":"Koshy AN","year":"2023","unstructured":"Koshy AN, Giustino G, Sartori S, et al.. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention. 2023, 18:1244-53. 10.4244\/EIJ-D-22-00654","journal-title":"EuroIntervention"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36335","article-title":"Efficacy, safety, and role of antiplatelet drugs in the management of acute coronary syndrome: a comprehensive review of literature","volume":"15","author":"Abubakar M","year":"2023","unstructured":"Abubakar M, Raza S, Hassan KM, et al.. Efficacy, safety, and role of antiplatelet drugs in the management of acute coronary syndrome: a comprehensive review of literature. Cureus. 2023, 15:10.7759\/cureus.36335","journal-title":"Cureus"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19158977","article-title":"Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status","volume":"19","author":"Pradhan A","year":"2022","unstructured":"Pradhan A, Tiwari A, Caminiti G, Salimei C, Muscoli S, Sethi R, Perrone MA. Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status. Int J Environ Res Public Health. 2022, 19:10.3390\/ijerph19158977","journal-title":"Int J Environ Res Public Health"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.780605","article-title":"Effects of clopidogrel, prasugrel and ticagrelor on microvascular function and platelet reactivity in patients with acute coronary syndrome undergoing coronary artery stenting. A randomized, blinded, parallel group trial","volume":"8","author":"Schnorbus B","year":"2021","unstructured":"Schnorbus B, Jurk K, Lackner KJ, Welk C, M\u00fcnzel T, Gori T. Effects of clopidogrel, prasugrel and ticagrelor on microvascular function and platelet reactivity in patients with acute coronary syndrome undergoing coronary artery stenting. A randomized, blinded, parallel group trial. Front Cardiovasc Med. 2021, 8:10.3389\/fcvm.2021.780605","journal-title":"Front Cardiovasc Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225771","article-title":"Gender-based differences in platelet function and platelet reactivity to P2Y12\u00a0inhibitors","volume":"14","author":"Ranucci M","year":"2019","unstructured":"Ranucci M, Aloisio T, Di Dedda U, Menicanti L, de Vincentiis C, Baryshnikova E. Gender-based differences in platelet function and platelet reactivity to P2Y12\u00a0inhibitors. PLoS One. 2019, 14:10.1371\/journal.pone.0225771","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet JP","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021, 42:1289-367. 10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00471-z","article-title":"NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 inhibitor: a contrarian view","volume":"21","author":"Angoulvant D","year":"2021","unstructured":"Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 inhibitor: a contrarian view. Am J Cardiovasc Drugs. 2021, 21:483-6. 10.1007\/s40256-021-00471-z","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke S","year":"2019","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, et al.. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019, 381:1524-34. 10.1056\/NEJMoa1908973","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01419-y","article-title":"The risk of dyspnea in patients treated with third-generation P2Y(12) inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhang N","year":"2020","unstructured":"Zhang N, Xu W, Li O, Zhang B. The risk of dyspnea in patients treated with third-generation P2Y(12) inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2020, 20:10.1186\/s12872-020-01419-y","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285466-comparative-efficacy-and-safety-of-novel-antiplatelets-and-standard-therapy-in-patients-with-coronary-artery-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T04:05:35Z","timestamp":1728792335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285466-comparative-efficacy-and-safety-of-novel-antiplatelets-and-standard-therapy-in-patients-with-coronary-artery-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.71333","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,12]]}}}